Business
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the closing of its underwritten public offering of 8,581,250 shares of its common stock, and to certain investors that so choose, pre-funded warrants to purchase 2,200,000 shares of its common stock at an exercise price of $0.0001 per share. The shares of common stoc
About this update from Bicara Therapeutics Inc.
[{"type":"image","alt":"Bicara Therapeutics Inc.","displaySize":"","headline":null,"caption":"Bicara Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/6ccfcafb8abd88270fbc9bc7dafef0fe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/N7aaUVu45bXz.VUeCxgrhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6ccfcafb8abd88270fbc9bc7dafef0fe","width":300,"height":86}},"lazy":false},{"type":"text","content":"BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the closing of its underwritten public offering of 8,581,250 shares of its common stock, and to certain investors that so choose, pre-funded warrants to purchase 2,200,000 shares of its common stock at an exercise price of $0.0001 per share. The shares of common stock sold include 1,406,250 shares pursuant to the option granted by Bicara to the underwriters, which option was exercised in full. The public offering price of each share of common stock was $16.00 and the public offering price of each pre-funded warrant was $15.9999. The aggregate gross proceeds to Bicara from this offering were approximately $172.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses.","length":955,"tagName":"p"},{"type":"text","content":"Bicara intends to use the net proceeds of the offering to further invest in and build its medical and commercial infrastructure to support a planned regulatory filing and commercial launch for ficerafusp alfa, if approved, in the U.S.; to further accelerate the development of ficerafusp alfa in 1L R/M HPV-negative HNSCC, including a less frequent dosing schedule; to fund manufacturing costs for ficerafusp alfa for ongoing and anticipated drug development efforts; to fund early signal-finding to support future indication expansion for ficerafusp alfa; and for other general corporate purposes.","length":598,"tagName":"p"},{"type":"text","content":"Morgan Stanley, TD Cowen, BofA Securities, Cantor and Stifel acted as joint book-running managers for the offering.","length":115,"tagName":"p"},{"type":"text","conten...